Comparable prognostic impact of BNP levels among HFpEF, Borderline HFpEF and HFrEF: a report from the CHART-2 Study
| Autor: | Satoshi Miyata, Kanako Tsuji, Yasuhiko Sakata, Shintaro Kasahara, Hajime Aoyanagi, Ruri Abe, Hiroaki Shimokawa, Chart Investigators, Masayuki Sato, Jun Takahashi, Kotaro Nochioka, Masanobu Miura, Takeo Onose, Takashi Shiroto, Takuya Oikawa, Takeshi Yamauchi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class 030204 cardiovascular system & hematology Risk Assessment Ventricular Function Left 03 medical and health sciences 0302 clinical medicine Japan Risk Factors Internal medicine Cause of Death Natriuretic Peptide Brain Natriuretic peptide Medicine Humans cardiovascular diseases 030212 general & internal medicine Prospective Studies Aged Heart Failure Ejection fraction business.industry Incidence Hazard ratio Mean age Stroke Volume Plasma levels medicine.disease Prognosis Cardiac surgery Heart failure Cohort cardiovascular system Cardiology Female Cardiology and Cardiovascular Medicine business Biomarkers Follow-Up Studies |
| Zdroj: | Heart and vessels. 33(9) |
| ISSN: | 1615-2573 |
| Popis: | We aimed to compare the usefulness of plasma levels of B-type natriuretic peptide (BNP) for long-term risk stratification among patients with heart failure (HF) with preserved left ventricular ejection fraction (LVEF) (HFpEF), borderline HFpEF, and HF with reduced LVEF (HFrEF) in the same HF cohort. In the CHART-2 Study (N = 10,219), we categorized 4301 consecutive Stage C/D HF patients (mean age 68.7 years, female 32.4%) into 3 groups: HFpEF (LVEF ≥ 50%, N = 2893), borderline HFpEF (LVEF 40–50%, N = 666), and HFrEF (LVEF ≤ 40%, N = 742). During the median 6.3-year follow-up, all-cause deaths occurred in 887 HFpEF, 330 borderline HFpEF, and 330 HFrEF patients. Although median BNP levels increased from HFpEF, borderline HFpEF to HFrEF (85.3, 126 and 208 pg/ml, respectively, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink